Page 8 - Demo

IN THE SPOTLIGHT: CONTINUED ANDY OFFREDA
What made you so successful during the selling competition in Vegas?
Confidence.... coming from (1) taking the time to slow down during the home study portion to really absorb the new information, available resources, and customer segmentation. (2) amazing breakout table facilitated by Kirk Childress and knowledge sharing generated among South Texas representatives during the workshops. Special shout to the representatives at my breakout table:
Samara Reed
John Guzman Gabriella Schnoor Tanya Fenderbosch Jody Parent
Miguel Zepeda Michael Smith Sheralee Six
Pearls you can share to generate dialogue with our new resources ?
ASCVD mini flow- creating urgency and opportunity to address the residual risk for patients w/T2D and ASCVD. Specifically...separate studies (non-branded slide) pointing out "ASCVD was the most prevalent CV complication among T2D patients" and "People with T2D have a 2-4X HIGHER Risk of Stroke or MI vs those without T2D", and statement of support (non-branded slide) from major medical societies and use of GLP-1 RA's with proven CVD benefit. With the awareness and after I pause, as I make your way to then tell the story about Ozempic (SUSTAIN 6), healthcare professionals really appreciate the value of a 26% RRR of MACE on the composite primary endpoint when added to standard of care.